BYSI - BeyondSpring Price-to-Projected Revenue Ratio

BeyondSpring Inc. (BYSI) transitioned to a virtual model by outsourcing all testing, which triggered growth, and the forward P/S trajectory confirms this momentum. The 37.40 mark serves as a key metric for the current valuation. This trend reflects physicians' confidence in immune protection during therapy and management's commitment to ensuring global access to new medications.

BeyondSpring, Inc. - BYSI Projected Price to Revenue (period 07/04/2022 - 09/30/2025)

Comprehensive metric breakdowns and analytics for BeyondSpring Inc (BYSI)

- market price and analyst price targets:

Price Chart BeyondSpring|BYSI - Price Target Chart

- market capitalization statistics:

Market Value BeyondSpring Inc|BYSI - Total Enterprise Value

- book value of equity indicators:

Book Value per Share BeyondSpring|BYSI - Book Value of Business|Market Cap to Net Assets Ratio beyondspringpharma.com|BYSI - Company Assets

- debt and liquidity data:

Total Debt to Equity Ratio BeyondSpring Inc.|BYSI - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio BeyondSpring Inc.|BYSI - Company Cumulative Indebtedness|Debts to Book Capitalization BeyondSpring Inc|BYSI - Company Long-Term Loans and Borrowings|Company Short-Term Debts BeyondSpring|Quick Liquidity beyondspringpharma.com

- financial results and valuation multiples details:

BYSI - Final Profit|Projected Future Earnings BeyondSpring Inc.|BYSI - P/E Multiple|Future Price to Earnings BeyondSpring Pharma|BYSI - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio BeyondSpring Inc|BYSI - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) BeyondSpring|BYSI - Earnings per share for the last twelve months|Quarterly EPS earnings growth beyondspringpharma.com|BYSI - Earnings per share growth rate in current year|Expected earnings per share growth for next year BeyondSpring Inc.

- revenue and sales proceeds data:

BYSI - Company Total Revenue|Company Projected Revenue BeyondSpring|BYSI - Price to Sales|Price-to-Projected Revenue Ratio BeyondSpring Inc

General company analysis:BeyondSpring BYSI

Manufactured products of beyondspringpharma.com

Investors assess the operational strength of assets through the ratio of market capitalization to expected sales, where the forward price-to-sales valuation trend reflects a real-time market reassessment of the business potential. For BeyondSpring Inc. (BYSI), the stability of its research staff minimizes operational risks, turning this indicator into a precise tool for analyzing the company's fundamental resilience as it reaches key development milestones.

Key competitors

Price-to-Projected Revenue Ratio Incyte INCY|Hutchison MediPharma - Price-to-Projected Revenue Ratio|NUVB - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Day One Biopharmaceuticals Inc|MNPR: Forward P/S Multiple|Projected Price to Revenue inhibrx.com INBX|Forward Price-to-Revenue Multiple IMAB|Market Cap to Future Revenue Ratio Fennec Pharma FENC|Forward Price-to-Revenue Multiple HRTX (Heron Therapeutics)|NVCT (Nuvectis Pharma, Inc) - Forward Price to Sales|Coherus Biosciences - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio CRBP (corbuspharma.com)|Cardiff Oncology Corp - Forward P/S Multiple|Forward Price to Sales BCAB (BioAtla, Inc.)|LIXT: Forward P/S Multiple|Market Cap to Future Revenue Ratio Citius Pharmaceuticals, Inc. (CTXR)|Price-to-Projected Revenue Ratio Cellectar Biosciences|BLRX: Forward Price to Sales|Forward P/S Multiple CANF|Forward P/S Multiple aprea.com (APRE)|Price-to-Projected Revenue Ratio Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Future Price to Revenue|NCNA: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio chimerix.com|CYCC: Forward P/S Multiple|GTHX (G1 Therapeutics) - Price-to-Projected Revenue Ratio|KRON (Kronos Bio Corp) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Kintara Pharma KTRA|Forward Price-to-Revenue Multiple ONCT (Oncternal Therapeutics)|PRTG - Market Cap to Future Revenue Ratio